Abstract
In this manuscript, we model and visualize the region-wise trends of the evolution to COVID-19 infections employing a SIR epidemiological model. The SIR dynamics are expressed using stochastic differential equations. We first optimize the parameters of the model using RMSE as loss function on the available data using L-BFGS-B gradient descent optimisation to minimise this loss function. This helps to gain better approximation of the model’s parameter for specific country or region. The derived parameters are aggregated to project future trends for the Indian subcontinent for next 180 days, which is currently at an early stage within the infection cycle. The projections are meant to function a suggestion for strategies for the socio-political counter measures to mitigate COVID-19. This study considers the current data for India from various open sources. The SIR models prediction is found following the actual trends till date. The inflection point analysis is important to find out which countries have reached their inflection point of the number of infection.
We found that if current restrictions like lockdown in India continues with same control, then India will observe itś peak in active patients count on 22 May 2020, it will take 28 August 2020 for 90% of the peak active infections to end. Inspired from the study of DDI Lab at Singapore university of technology and design (SUTD), this study additionally tries to model and quantify the variations in the count of active patients in the country which might occur due to effect of waiver in restrictions. It should be noted that these results were predicted using COVID-19 data of India till 03 May 2020.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no funding for this project.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: ankitbarai507{at}gmail.com, Email: singhanuradha87{at}gmail.com, Email: dr.amol.d.shinde{at}gmail.com
